CoChat

Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration

Open access
McShane, Lisa M, Cavenagh, Margaret M, Lively, Tracy G, Eberhard, David A, Bigbee, William L, Williams, P Mickey, Mesirov, Jill P, Polley, Mei-Yin C, Kim, Kelly Y, Tricoli, James V, Taylor, Jeremy MG, Shuman, Deborah J, Simon, Richard M, Doroshow, James H, Conley, Barbara A · 2013 · BMC Medicine
Cited by 140

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

High-throughput 'omics' technologies that generate molecular profiles for biospecimens have been extensively used in preclinical studies to reveal molecular subtypes and elucidate the biological mechanisms of disease, and in retrospective studies on clinical specimens to develop mathematical models to predict clinical endpoints. Nevertheless, the translation of these technologies into clinical tests that are useful for guiding management decisions for patients has been relatively slow. It can be difficult to determine when the body of evidence for an omics-based test is sufficiently comprehensive and reliable to support claims that it is ready for clinical use, or even that it is ready for definitive evaluation in a clinical trial in which it may be used to direct patient therapy. Reasons for this difficulty include the exploratory and retrospective nature of many of these studies, the complexity of these assays and their application to clinical specimens, and the many potential pitfalls inherent in the development of mathematical predictor models from the very high-dimensional data generated by these omics technologies. Here we present a checklist of criteria to consider when evaluating the body of evidence supporting the clinical use of a predictor to guide patient therapy. Included are issues pertaining to specimen and assay requirements, the soundness of the process for developing predictor models, expectations regarding clinical study design and conduct, and attention to regulatory, ethical, and legal issues. The proposed checklist should serve as a useful guide to investigators preparing proposals for studies involving the use of omics-based tests. The US National Cancer Institute plans to refer to these guidelines for review of proposals for studies involving omics tests, and it is hoped that other sponsors will adopt the checklist as well.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1741-7015-11-220

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 140

Metadata

Authors
McShane, L. M., Cavenagh, M. M., Lively, T. G., Eberhard, D. A., Bigbee, W. L., Williams, P. M., Mesirov, J. P., Polley, M.-Y. C., Kim, K. Y., Tricoli, J. V., Taylor, J. M., Shuman, D. J., Simon, R. M., Doroshow, J. H., & Conley, B. A.
Venue
BMC Medicine
Published
2013-10-17
Volume
11
Issue
1
Pages
220-220
ISSN
1741-7015 (ISSN-L)
OpenAlex
W1974333176
Cited by
140
References
18
FWCI
4.97
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. https://app.cochat.ai/papers/10.1186/1741-7015-11-220
The paper
McShane, L. M., Cavenagh, M. M., Lively, T. G., Eberhard, D. A., Bigbee, W. L., Williams, P. M., Mesirov, J. P., Polley, M.-Y. C., Kim, K. Y., Tricoli, J. V., Taylor, J. M., Shuman, D. J., Simon, R. M., Doroshow, J. H., & Conley, B. A. (2013). Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Medicine. https://doi.org/10.1186/1741-7015-11-220

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.